Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medicofarma BiotechWAR:MDB -1.03%30 PS Ratio is 193.00 as of Sep. 07, 2026, which is 1975% above its 10-year median of 9.30. GuruFocus rates WAR:MDB with a GF Score™ of 30/100 and a GF Value™ of zł0.12 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 955 Drug Manufacturers companies, Medicofarma Biotech ranks worse than 98.74% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Medicofarma Biotech's share price is zł0.386.
Medicofarma Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was zł0.00. Hence, Medicofarma Biotech's PS Ratio for today is 193.00.
The historical rank and industry rank for Medicofarma Biotech's PS Ratio or its related term are showing as below:
WAR:MDB'
s PS Ratio Range Over the Past 10 Years
Min: 0.24 Med: 9.3 Max: 498
Current: 193
During the past 13 years, Medicofarma Biotech's highest PS Ratio was 498.00. The lowest was 0.24. And the median was 9.30.
WAR:MDB's PS Ratio is ranked worse than 98.74% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.35
vs WAR:MDB: 193.00
Medicofarma Biotech SA revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Medicofarma Biotech was -50.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -68.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -60.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -43.20% per year.
During the past 13 years, Medicofarma Biotech's highest 3-Year average Revenue per Share Growth Rate was 16.70% per year. The lowest was -72.70% per year. And the median was -10.40% per year.
Medicofarma Biotech (WAR:MDB) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Medicofarma Biotech PS Ratio Related Terms
Medicofarma Biotech PS Ratio Historical Data
* Premium members only.
The historical data trend for Medicofarma Biotech's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medicofarma Biotech's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicofarma Biotech PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicofarma Biotech's PS Ratio distribution charts can be found below:
* The bar in red indicates where Medicofarma Biotech's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Medicofarma Biotech's Share Price of today is zł0.386. Medicofarma Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Medicofarma Biotech (WAR:MDB) has a PS Ratio of 193.00 as of Sep. 07, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Medicofarma Biotech and its competitors. This is 1975% above median its historical median of 9.30. Over the past decade, Medicofarma Biotech's PS Ratio has ranged from 0.24 to 498.00. According to the industry distribution chart, Medicofarma Biotech ranks #943 out of 955 companies in the Drug Manufacturers industry, placing it in the top 98.7%.
Is Medicofarma Biotech's PS Ratio too high?
Medicofarma Biotech's current PS Ratio of 193.00 is 1975% above median its 10-year median of 9.30. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 498.00. The Drug Manufacturers industry median PS Ratio is 2.35. Medicofarma Biotech's value of 193.00 is 8112.8% above this industry median. Based on the distribution chart, Medicofarma Biotech ranks #943 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medicofarma Biotech has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medicofarma Biotech's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medicofarma Biotech ranks #943 out of 955 companies for PS Ratio. This places Medicofarma Biotech in the lower half of its industry. The industry median PS Ratio is 2.35. Medicofarma Biotech's value of 193.00 is 8112.8% above this benchmark. Historically, Medicofarma Biotech's own PS Ratio has ranged from 0.24 to 498.00 over the past decade. While the company's 10-year median is 9.30 vs. the industry median of 2.35, Medicofarma Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.35, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicofarma Biotech's current PS Ratio of 193.00 is 8112.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Medicofarma Biotech and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicofarma Biotech's current PS Ratio is 193.00, which is 1975% above median its own 10-year median of 9.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicofarma Biotech stock overvalued right now?
Based on GuruFocus' analysis, Medicofarma Biotech (WAR:MDB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.12, compared to a current price of zł0.39 — trading 221.7% above its estimated fair value. The current PS Ratio is 193.00, which is 1975% above median its 10-year median of 9.30 and 8112.8% above the Drug Manufacturers industry median of 2.35. Medicofarma Biotech's overall GF Score™ is 30/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Medicofarma Biotech (WAR:MDB), the current PS Ratio is 193.00 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicofarma Biotech (WAR:MDB) Overvalued in 2026?
Based on GuruFocus' analysis, Medicofarma Biotech stock appears to be overvalued.
The current stock price of zł0.39 is trading 221.7% above its estimated GF Value™ of zł0.12.
GuruFocus considers Medicofarma Biotech to be Significantly Overvalued.
Key valuation signals for WAR:MDB:
PS Ratio: 193.00 (1975% above median its 10-year median of 9.30)
GF Value™: zł0.12 vs. price of zł0.39 (221.7% above fair value)
Industry Position: 8112.8% above the Drug Manufacturers median (#943 of 955)
No single metric tells the full story. See the WAR:MDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicofarma Biotech SA operates in the pharmaceutical industry. The company specializes in contract manufacturing of medical devices, medicinal products and dietary supplements. The business is spread across Austria, Czech Republic, Spain, Ireland, Canada, Germany, Norway, Sweden, Great Britain, and Italy.
30GF Score
Get the complete analysis for WAR:MDB
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:MDB has been successfully added to your 
